HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Lisofylline

HCID 501254
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
100324-81-0
Standard SMILES
C[C@@H](O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O
InChIKey
NSMXQKNUPPXBRG-SECBINFHSA-N
Molecular formula
C13H20N4O3
Average molar mass
280.32 g/mol
Monoisotopic mass
280.15354051

Overview

(R)-lisofylline is a 1-(5-hydroxyhexyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione that has (R)-configuration. A synthetic small molecule which was under development for the treatment of type 1 diabetes mellitus. It has a role as an immunomodulator and an anti-inflammatory agent. It is an enantiomer of a (S)-lisofylline.

Names & identifiers

Preferred name
Lisofylline
IUPAC
1-[(5R)-5-hydroxyhexyl]-3,7-dimethylpurine-2,6-dione
English name
1-(5-hydroxyhexyl)-3,7-dimethyl-purine-2,6-dione
Molecular formula
C13H20N4O3
Molecular weight
280.32

Names & synonyms

(R)-LisofyllineLISOFYLLINE100324-81-0ProTecLisophyllineCT-1501RlisofilinaCT 1501R1-[(5R)-5-hydroxyhexyl]-3,7-dimethylpurine-2,6-dioneLisofylline, (r)-lisofyllinumCT1501R
Show more names
(R)-Lisofylline, 10 mM in DMSO1-(5-hydroxyhexyl)-3,7-dimethyl-purine-2,6-dione3,7-Dihydro-1-[(5R)-5-hydroxyhexyl]-3,7-diMethyl-(R)-1-(5-Hydroxyhexyl)-3,7-dimethyl-1H-purine-2,6(3H,7H)-dione
(R)-Lisophylline1-[(R)-5-hydroxyhexyl]theobromine1-(5R-Hydroxyhexyl)-3,7-dimethylxanthineDTXSID7058709CHEBI:143527L1F2Q2X9561-((R)-5-Hydroxyhexyl)theobromine1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione

Database identifiers

CAS
100324-81-0
PubChem CID
501254
DTXSID
DTXSID7058709
ChEMBL
CHEMBL1411

Properties

Computed structural properties

XLogP
0.7
Topological polar surface area
78.7 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
4
Rotatable bonds
5
Heavy atoms
20
Formal charge
0
Complexity
390

Experimental & physicochemical properties

Drugs · 2 items

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Metabolite of Pentoxifylline

Physicochemical properties

Melting point
105 · 105-107°C
alpha
20 · D20 -5.6° (c = 6.7 in ethanol)
Boiling point
511.2 · 511.2±56.0 °C(Predicted)
Density
1.32 · 1.32±0.1 g/cm3(Predicted)
storage temp.
-20 °C · Hygroscopic, -20°C Freezer, Under Inert Atmosphere
solubility
Chloroform, Methanol
form
Solid
pka
15.22 · 15.22±0.20(Predicted)
color
White to Off-White
Stability
Hygroscopic
FDA UNII
1 F2Q2X956 · L1F2Q2X956
Symbol(GHS)
7 · GHS07

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Safety data

Signal word
Warning
Symbol(GHS)
GHS07
Hazard statements
H302
Precautionary statements
P264-P270-P301+P312-P330-P501

Chemistry & industry

Pharmacology

Metabolism/MetabolitesLisofylline has known human metabolites that include pentoxifylline and lisofylline 4,5-diol.
MeSH Pharmacological Classification · 4 items

Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.

Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells.

Applications

UsesA major metabolite of Pentoxifylline. Methylxanthine that inhibits production of phosphatidic acid during the inflammatory response. Immunomodulator.

Additional notes · 1 item

Related reactions

2 records
New reaction record
HRID 348782 reaction equation
HRID 348782As reactant
HRID 553329 reaction equation
HRID 553329As reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
ChEBI
CHEBI:143527
UNII
L1F2Q2X956
Nikkaji
J731.039K
Signal word
Warning
Hazard statements
302 · H302
Precautionary statements
264 · P264-P270-P301+P312-P330-P501

DefinitionChEBI: (R)-lisofylline is a 1-(5-hydroxyhexyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione that has (R)-configuration. A synthetic small molecule which was under development for the treatment of type 1 diabetes mellitus. It has a role as an anti-inflammatory agent and an immunomodulator. It is an enantiomer of a (S)-lisofylline.